# Effectiveness of Riboflavin-Moxifloxacin Amniotic Membrane as an Adjuvant for PACK-CXL in Moderate to Severe Infectious Keratitis

> **NCT07559149** · PHASE2 · COMPLETED · sponsor: **Gadjah Mada University** · enrollment: 32 (actual)

## Conditions studied

- Infected Corneal Ulcers
- CXL

## Interventions

- **COMBINATION_PRODUCT:** Riboflavin-Moxifloxacin Amniotic Membrane
- **OTHER:** Standard PACK-CXL

## Key facts

- **NCT ID:** NCT07559149
- **Lead sponsor:** Gadjah Mada University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-07
- **Primary completion:** 2025-02-13
- **Final completion:** 2025-08-14
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07559149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07559149, "Effectiveness of Riboflavin-Moxifloxacin Amniotic Membrane as an Adjuvant for PACK-CXL in Moderate to Severe Infectious Keratitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07559149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*